Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Safety and Efficacy Study of Autologous Neo-Kidney Augment in Type 2 Diabetes and Chronic Kidney Disease
2015-003156-49Phase 2Completed
- Sponsor
- Regenerative Medical Solutions
- Start
- Sep 2015
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilparencel in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM), sponsored by Regenerative Medical Solutions. Primary endpoints: Procedure/product-related adverse events and Stabilization of renal function. Started Sep 2015; status: completed.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2015-003156-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003156-49.